BR9914066A - degrading polypeptide of human complement C3 Streptococcus pneumoniae - Google Patents

degrading polypeptide of human complement C3 Streptococcus pneumoniae

Info

Publication number
BR9914066A
BR9914066A BR9914066A BR9914066A BR9914066A BR 9914066 A BR9914066 A BR 9914066A BR 9914066 A BR9914066 A BR 9914066A BR 9914066 A BR9914066 A BR 9914066A BR 9914066 A BR9914066 A BR 9914066A
Authority
BR
Brazil
Prior art keywords
kd
streptococcus pneumoniae
human complement
complement c3
degrading
Prior art date
Application number
BR9914066A
Other languages
Portuguese (pt)
Inventor
Margaret K Hostetter
David J Finkel
Qi Cheng
Bruce A Green
Amy W Masi
Original Assignee
Univ Minnesota
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10173698P priority Critical
Priority to US28309499A priority
Application filed by Univ Minnesota, American Cyanamid Co filed Critical Univ Minnesota
Priority to PCT/US1999/022362 priority patent/WO2000017370A1/en
Publication of BR9914066A publication Critical patent/BR9914066A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Abstract

"POLIPEPTìDIO DEGRADADOR DE C3 DE COMPLEMENTO HUMANO DE STREPTOCOCCUS PNEUMONIAE". "SUPPLEMENT C3 polypeptide degrading OF HUMAN Streptococcus pneumoniae." A presente invenção refere-se à identificação e uso de uma família de polipeptídios degradando complemento humano C3, expressos por S. pneumoniae. The present invention relates to the identification and use of a family of polypeptides by degrading human complement C3 expressed by S. pneumoniae. Os polipeptídios tem pesos moleculares de cerca de 15 kD a cerca de 20 kD ou cerca de 75 kDa a cerca de 95 kDa, por exemplo. The polypeptides has molecular weights of about 15 kD to about 20 kD or about 75 kD to about 95 kD, for example. Os polipeptídios preferidos desta invenção incluem as seq³ências de aminoácido de SEQ ID N<0>: 2 e SEQ ID N<0>: 5. Preferred polypeptides of this invention include those of SEQ ID NO: seq³ências amino acid <0>: 2 and SEQ ID N <0>: 5.
BR9914066A 1998-09-24 1999-09-24 degrading polypeptide of human complement C3 Streptococcus pneumoniae BR9914066A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10173698P true 1998-09-24 1998-09-24
US28309499A true 1999-03-31 1999-03-31
PCT/US1999/022362 WO2000017370A1 (en) 1998-09-24 1999-09-24 HUMAN COMPLEMENT C3-DEGRADING POLYPEPTIDE FROM $i(STREPTOCOCCUS PNEUMONIAE)

Publications (1)

Publication Number Publication Date
BR9914066A true BR9914066A (en) 2002-04-23

Family

ID=26798575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914066A BR9914066A (en) 1998-09-24 1999-09-24 degrading polypeptide of human complement C3 Streptococcus pneumoniae

Country Status (9)

Country Link
EP (1) EP1115875A1 (en)
JP (1) JP2002526082A (en)
CN (1) CN1352691A (en)
AU (1) AU6060899A (en)
BR (1) BR9914066A (en)
CA (1) CA2343931A1 (en)
IL (1) IL142017D0 (en)
MX (1) MXPA01003073A (en)
WO (1) WO2000017370A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT942983E (en) * 1996-10-31 2007-02-28 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JP4689044B2 (en) 1998-12-21 2011-05-25 メディミューン,インコーポレーテッド Streptococcus pneumoniae proteins and immunogenic fragments for vaccine use
EP1950302B1 (en) 1998-12-23 2012-12-05 ID Biomedical Corporation of Quebec Streptococcus antigens
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
KR101170203B1 (en) * 1998-12-23 2012-07-31 아이디 바이오메디칼 코포레이션 Novel Streptococcus antigens
AU7038101A (en) * 2000-06-20 2002-01-02 Shire Biochem Inc Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
US8329169B2 (en) * 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
SI1868645T1 (en) 2005-04-08 2012-04-30 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5219819B2 (en) 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッドCatalyst Biosciences, Inc. Modified proteases that inhibit complement activation
HUE041979T2 (en) 2005-12-22 2019-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SI2167121T1 (en) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
AU2009237647A1 (en) 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
BR112013029514A2 (en) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa immunogenic composition, vaccine, and method of treating or preventing a disease
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
PT942983E (en) * 1996-10-31 2007-02-28 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
CN1253589A (en) * 1997-04-24 2000-05-17 美国明尼苏达州大学 Human complement C3-degrading proteinase from streptococcus pneumoniae
AU9510598A (en) * 1997-09-24 1999-04-12 American Cyanamid Company Human complement c3-degrading proteinase from (streptococcus pneumoniae)

Also Published As

Publication number Publication date
JP2002526082A (en) 2002-08-20
IL142017D0 (en) 2002-03-10
CN1352691A (en) 2002-06-05
EP1115875A1 (en) 2001-07-18
AU6060899A (en) 2000-04-10
MXPA01003073A (en) 2002-04-24
CA2343931A1 (en) 2000-03-30
WO2000017370A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
Kühn et al. Mapping of the domains required for decay acceleration activity of the human factor H‐like protein 1 and factor H
CN1210305C (en) Neisseria meningitidis antigen and composition
Hirabayashi et al. Complete primary structure of a galactose-specific lectin from the venom of the rattlesnake Crotalus atrox. Homologies with Ca2 (+)-dependent-type lectins.
RU2203268C2 (en) Modified amino acids, compositions for delivery of biologically active agents to selected biological systems, method for preparing such compositions and pharmacological composition
Medved' et al. Structural organization of C‐terminal parts of fibrinogen Aα‐chains
BR8102164A (en) Process for synthesizing within a bacterial host, and secreting through the membrane of the host, a protein or polypeptide slecionada and vehicle cloning and host transformed as a last
WO2001055343A8 (en) Nucleic acids, proteins, and antibodies
DE3586853D1 (en) Immunologically active peptides suitable for einfuehrung of immunization against malaria and the coding of genes.
TR199800825T2 (en) Farnesyl protein transfer inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives.
DE69509628D1 (en) N-terminally chemically modified protein compositions and methods-
NO336528B1 (en) Antistoffinhibitorer of GDF-8 and use thereof
TR200200662T2 (en) Secretase in Alzheimer&#39;s disease
CA2102208A1 (en) Binding domains in notch and delta proteins
EP1803733A3 (en) Use of a polypeptide comprising the extracellular domains of IL-20RA and IL-20RB for the treatment of inflammation
NO954342L (en) Erytropoietinanalogblandinger, and methods for the preparation thereof
NO308397B1 (en) Disinfectant composition, fremgangsmÕte for preparation and uses thereof, as well as two-pack system
YU8997A (en) Purified protein having serinic proteaze inhibiting activity and pharmaceutical preparation containing them
CY1118037T1 (en) Abeta antibodies and their use h
BR0009323A (en) Human antibodies that bind human IL-12 and methods for producing
CA2226087A1 (en) Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
AT130327T (en) Polyethylene glycol derivatives, modified peptides thereof, their manufacture and use of the modified peptide.
EE05075B1 (en) POL1212 amino acid &#34;rjestust-encoding DNA, the expression vector containing, modified porcine factor VIII, the p? Hinev pharmaceutical composition and method for the modified porcine factor VIII having the amino acid&#34; preparation of a protein having rjestust
BR9710994A (en) anticonvulsants useful derivatives in the treatment of obesity.
RU2222597C2 (en) Protein receptor of class vip3, dna sequence encoding thereof and method for detection or isolation of homologs of indicated protein receptor or dna sequence encoding thereof
AR012540A1 (en) ANTIBODY PHARMACEUTICAL COMPOSITION lyophilised monoclonal or polyclonal, process for their production

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired